PHILADELPHIA, PA — Aldevron, a unit of Danaher Corporation (NYSE: DHR), and Minaris expanded a licensing agreement tied to lentiviral plasmid manufacturing, deepening a partnership aimed at accelerating development timelines for gene-modified cell therapies including CAR-T treatments.
The renewed agreement gives biotechnology developers broader access to an off-the-shelf lentiviral plasmid system used in cell and gene therapy manufacturing, an area facing increasing pressure to reduce production bottlenecks, regulatory complexity, and supply-chain risk as more therapies move toward commercialization.
Under the arrangement, Aldevron will continue manufacturing and supplying Oxgene-designed plasmids across research-grade, GMP Source, and full cGMP production standards. The agreement also expands developer access to Minaris’ Oxgene Development Centre in London, where companies can optimize plasmids and gene constructs intended to improve viral vector productivity.
The partnership centers on Aldevron’s pALD-Lenti platform, a four-plasmid lentiviral vector production system used in applications such as CAR-T and TCR-T therapies.
“Our collaboration with Minaris brings together complementary strengths—world-class plasmid design and cGMP manufacturing innovation—in a way that reduces risk and complexity for developers at every stage of the pipeline,” Venkata Indurthi said in a statement.
The companies are positioning the expanded agreement around demand for scalable manufacturing inputs as cell and gene therapy developers seek to shorten timelines between early-stage research and clinical trials.
Oxgene, which operates as Minaris’ advanced technology division, focuses on viral vector platforms, plasmid engineering, and cell-line development. Lentiviral vectors are widely used in gene-modified therapies because they can deliver genetic material into target cells.
“Our focus has always been on designing robust, high-performing plasmid systems that translate seamlessly into scalable vector production,” Eytan Abraham said. “By combining that design expertise with Aldevron’s manufacturing strength, we help ensure developers have reliable, high-quality starting materials that reduce risk, streamline development, and support a clear path toward clinical and commercial success.”
Financial terms of the agreement were not disclosed.
The expanded partnership comes as contract manufacturers and suppliers race to build infrastructure supporting the growing gene therapy sector, where developers face high production costs, specialized regulatory requirements, and limited manufacturing capacity.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.